Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.39 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GRM8 | O00222 | 1/20 | 0.39 |
| ▸ | GRM6 | O15303 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16336444 | 1.00 | CYP2C19 (0.39) | CYP2C19LMNAGRM2GRM3GRM4 | |
| SCHEMBL709793 | 1.00 | CYP2C19 (0.39) | CYP2C19LMNAGRM2GRM3GRM4 | |
| SCHEMBL15684228 | 0.88 | CYP2C19 (0.46) | CYP2C19LMNAGRM2GRM3GRM4 | |
| SCHEMBL30298830 | 0.81 | PDK2 (0.36) | CYP2C19LMNAGRM2GRM3GRM4 | |
| SCHEMBL26631347 | 0.77 | CYP2C19 (0.50) | CYP2C19LMNAGRM2GRM3GRM4 | |
| SCHEMBL710044 | 0.77 | CYP2C19 (0.50) | CYP2C19LMNAGRM2GRM3GRM4 | |
| SCHEMBL31214195 | 0.76 | CYP1A2 (0.39) | CYP2C19LMNAGRM2GRM3GRM4 | |
| Hydrochloric Acid SCHEMBL27035460 | 0.75 | GRM2 (0.46) | CYP2C19LMNAGRM2GRM3GRM4 | |
| SCHEMBL12971036 | 0.74 | TSHR (0.46) | CYP2C19LMNAGRM2GRM3GRM4 | |
| SCHEMBL26906347 | 0.74 | TSHR (0.33) | TSHRHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109670-A9 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-06 | — | — | US | disclosed |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-26 | — | — | US | disclosed |
| EP-3924337-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2021-12-22 | — | — | EP | disclosed |
| CN-113677666-A | Substituted bicyclic compounds as farnesoid X receptor modulators | 百时美施贵宝公司 | 2021-11-19 | — | — | CN | disclosed |
| WO-2020168148-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109670-A9 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | CYP2C19 1139/4885LMNA 3646/4885GRM2 1024/4885 |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | CYP2C19 1139/4885LMNA 3646/4885GRM2 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.